At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
A form Arginine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement·interventional·Posted Feb 2, 2015·Updated Feb 2, 2015
In Brief
A clinical study evaluating A form Arginine and B form Arginine for Overweight and Hypertriglyceridemic Waist. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the metabolic fate of two oral forms of L-Arginine in healthy subjects featuring metabolic syndrome related risk factors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOverweight, Hypertriglyceridemic Waist
CountriesFrance
CollaboratorsInstitut de Recherche Pierre Fabre, Hospital Avicenne, Adeprina
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
Primary CompletionMay 2013
First PostedFeb 2015
TodayJul 2026
First PostedFeb 2, 2015
Enrollment StartMar 1, 2013
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.4 years ago
Interventions
A form Argininedietary
3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
B form Argininedietary
3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week